Madrigal Pharmaceuticals, Inc. (MDGL)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 206.92 |
| Open | 206.40 |
| Bid | 205.15 x 100 |
| Ask | 205.69 x 100 |
| Day's Range | 204.08 - 208.74 |
| 52 Week Range | 119.76 - 302.68 |
| Volume | |
| Avg. Volume | 545,166 |
| Market Cap | 4.415B |
| Beta (5Y Monthly) | -0.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -23.13 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 363.79 |
Insider MonkeyMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript May 7, 2024 Madrigal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-7.38 EPS, expectations were $-6.06. MDGL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank […]
- GuruFocus.com
Madrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
Insights into MDGL's financial health, strategic milestones, and initial hurdles in the commercial launch of its NASH treatment.
- GuruFocus.com
Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launch
First Quarter Performance Highlights and Strategic Updates
© 2024 Yahoo. All rights reserved.